AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06466993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention of standardized relaxing breathing
Description: Relaxing breathing standardized to 6 respiratory cycles per minute that occur during rotation time before next station of OSCE start
Study NCT06466993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention of standardized relaxing breathing
Description: Relaxing breathing standardized to 6 respiratory cycles per minute that occur during rotation time before next station of OSCE start
Study NCT04722796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)
Description: Transcatheter aortic valve replacement (TAVR) with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)
Study NCT04722796 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAVR with Venus A plus using annular sizing and THV implantation technique
Description: Transcatheter aortic valve replacement (TAVR) with Venus A plus using annular sizing and THV implantation technique (Traditional sizing strategy)
Study NCT05367141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CDSS (MedicBK)
Description: Clinical decision support system (MedicBK) is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care.
Study NCT05094817 — intervention group
Intervention type: OTHER
Intervention: Brain Health Assessment
Description: BHA is a free, self-administered online cognitive screening test developed in Toronto at Baycrest (www.cogniciti.com). BHA has been validated against a gold standard neuropsychological assessment for detecting amnestic MCI (aMCI) - the most common type of MCI - in community dwelling older adults. BHA has high sensitivity (.78), specificity (.78), PPV (.82), NPV (.74), and was better than MoCA for identifying aMCI. ROC curves showed an AUC of 0.75 for detecting aMCI from normal subjects. BHA measures memory and executive attention processes sensitive to subtle cognitive changes associated with normal aging and MCI. BHA can be completed from a patient's home or can be self-administered in hospital.
Study NCT05094817 — intervention group
Intervention type: OTHER
Intervention: Demographics questionnaire
Description: To compare the sociodemographic characteristics of patients completing Cogniciti's BHA vs. those who are not able to complete the BHA.
Study NCT05094817 — intervention group
Intervention type: OTHER
Intervention: PHQ-2
Description: PHQ-2 is a shortened version of PHQ-9 which is originally a component of the longer Patient Health Questionnaire. The tool incorporates DSM-IV depression criteria and other leading major depressive symptoms into brief self-reported instruments. PHQ-2 inquires about the degree to which an individual experiences depression and anhedonia (inability to feel pleasure) over the past two weeks. The tool is not for final diagnosis of depression or monitoring its severity but only for the purpose of screening for the condition.The questionnaire comprises of the first two questions from PHQ-9, each item is scored 0-3. Therefore, the PHQ-2 score ranges from 0-6.
Study NCT05094817 — intervention group
Intervention type: OTHER
Intervention: AFT
Description: AFT is a free, rapid cognitive assessment commonly used to assess semantic language ability. Language is one of the earliest functions affected by AD and naming and semantical knowledge seems to be particularly affected. The identification of language deficits may pick up signs of neurological decline preceding the appearance of clinical symptoms. Milder forms of cognitive impairment such as MCI may also show language deficits if language is one of the domains affected.
Study NCT05094817 — intervention group
Intervention type: OTHER
Intervention: GAI-SF
Description: GAI-SF is a 5-item questionnaire derived from the original 20-item Geriatric Anxiety Inventory (GAI).In the population of community dwelling older women GAI-SF was developed in, a cut-off score of 3 yields a specificity of 87% and sensitivity of 75%. This highly accessible questionnaire is suitable for everyday use in a range of health-care settings. It has been employed amongst older adults in primary care settings, nursing homes, geriatric psychiatry patients and amongst clinical geriatric participants with co-morbid anxiety and unipolar mood disorder and their controls.
Study NCT05094817 — intervention group
Intervention type: OTHER
Intervention: pain VAS
Description: The VAS is a unidimensional measure of pain intensity. The VAS tries to measure a continuous characteristic or attitude signifying the intensity or frequency of symptoms. The scale ranges from 0-10, with 0 = no pain to 10 = worst pain.
Study NCT05094817 — intervention group
Intervention type: OTHER
Intervention: IADL
Description: Instrumental activities such as preparing meals or managing finances allow individuals to maintain their health while living on their own. The IADL measures the ability of older adults to manage their daily activities, as well as the impact, if any, cognitive decline would have on these activities. Scores range from 0-5 for men, and 0-8 for women, with higher sores being more independent and higher functioning.
Study NCT05094817 — intervention group
Intervention type: OTHER
Intervention: FAM CAM
Description: FAM-CAM was derived from the CAM instrument in order to screen for delirium by interviewing family members or caregivers of the patient. They are asked specific questions about any new or sudden changes in the patient's activity, behavioural or cognitive status. FAM-CAM showed good sensitivity and specificity in the original study where caregivers of elderly patients with pre-existing cognitive impairment were interviewed.
Study NCT05094817 — intervention group
Intervention type: OTHER
Intervention: 4AT
Description: The 4AT is a rapid tool for delirium detection that has previously been used in a surgical setting. The 4Ats test for the patient's alertness, mental state, attention, and signs of acute change. Across 17 studies, the pooled sensitivity and specificity of 4AT was 0.86 and 0.89. The 4AT will be administered after the patient has completed surgery, prior to discharge.
Study NCT05094817 — intervention group
Intervention type: OTHER
Intervention: BHA Usability Survey
Description: The survey aims to assess system usability and acceptability based on standard questions adapted from the validated System Usability Scale. The questions evaluate satisfaction, experience with technology, and comfort level, as well as questions targeting usability concerns typically experienced by older adults, such as typeface and font size, consistent navigation, and writing style.
Study NCT05094817 — intervention group
Intervention type: OTHER
Intervention: Clinical Frailty Scale
Description: CFS is a 9-item scale that uses clinical descriptors and pictographs and is an easily applicable tool to stratify older adults according to level of vulnerability. The CFS divides patients into 9 classes from very fit (CFS = 1) to terminally ill (CFS = 9). It is easy to use and may readily be administered in a clinical setting, an advantage over the tools previously developed. The scale helps in objective early identification of older adults with frailty in acute care units and helps to target interventions to prevent complications and to implement effective discharge planning.
Study NCT05065567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droperidol
Description: Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV
Study NCT05065567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 5mg haloperidol IM
Study NCT05065567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to ondansetron
Study NCT05995041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
Description: Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
Study NCT04810611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti-TIM3 monoclonal antibody
Study NCT04810611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Anti-TGF-β monoclonal antibody
Study NCT04810611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: Anti-IL-1β monoclonal antibody
Study NCT06312241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training-Silver BeWell
Description: Metacognitive Training- Silver BeWell is a cognitive behavioral based group intervention, which focuses on helping participants gain (metacognitive) distance from thought and behavioral patterns as well as behaviors and ER-strategies that are implicated in the onset of depression and reduced overall mental well-being. In 10 modules, MCT-Silver addresses issues specific to later life such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life, acceptance of negative feelings and resilience. In the training participants are made aware of information processing biases that have been shown to contribute to the onset of depression through engaging exercises using examples from daily life. Groups are comprised of up to 10 participants. Each session is 90 minutes.
Study NCT04860622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum thyroid function tests
Description: At the first hospital visit, the blood tests will be made for TSH, FT4, FT3, and beta HCG concentration measurement
Study NCT06135363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC1011
Description: SC1011 tablet
Study NCT06135363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: SC1011-matching placebo tablet
Study NCT04754230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)
Description: Medication administered 15 minutes prior to end of surgery.
Study NCT04892251 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MORE+KAP
Description: Mindfulness-Oriented Recovery Enhancement plus two sessions where 0.5 to 1.5 mg/kg of ketamine are administered intramuscularly
Study NCT04892251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MORE
Description: Mindfulness-Oriented Recovery Enhancement
Study NCT04808193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants will fill in the survey
Study NCT04855071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-ablative radiofrequency application
Description: Non-ablative radiofrequency application will be applied with MJS intracavitary probe, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a frequency that will be individualized according to the maximum level of energy absorption by the patient's tissues (between 0.8-1.2MHz) and with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session). In addition, they will be applied 1 session per week. The treatment will last 8 weeks.
Study NCT04855071 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual intervention
Description: The usual intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.
Study NCT04855071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual intervention
Description: The usual intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.
Study NCT05485883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Lenvatinib
Description: Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
Study NCT04485260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: administered by mouth
Study NCT04485260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: administered by mouth
Study NCT04764344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: 2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
Study NCT04764344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron
Study NCT06508359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension
Study NCT06508359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension
Study NCT06508359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Prophylactic or rescue phenylephrine for spinal anesthesia-induced hypotension
Study NCT06508359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Prophylactic or rescue phenylephrine for spinal anesthesia-induced hypotension
Study NCT04527419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systematically mediastinal lymph node dissection
Description: Systematically mediastinal lymph node dissection will be performed.
Study NCT04527419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No mediastinal lymph node dissection
Description: No mediastinal lymph node dissection will be performed.
Study NCT04893499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chios mastic water
Description: Participants randomized to this intervention arm will be provided with a sparkling water enriched with the natural mastic aqueous extract (0.06%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
Study NCT04893499 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo water
Description: Participants randomized to this intervention arm will be provided with a standard sparkling water and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
Study NCT04893499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chios mastic fruit juice
Description: Participants randomized to this intervention arm will be provided with a sparkling fruit juice enriched with the natural mastic aqueous extract (0.55%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
Study NCT04893499 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo fruit juice
Description: Participants randomized to this intervention arm will be provided with a standard sparkling fruit juice and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
Study NCT05661045 — intervention group
Intervention type: PROCEDURE
Intervention: low-flow anesthesia
Description: Changes in blood carboxyhemoglobin levels as a result of exposure to rebreathing during low-flow anaesthesia.
Study NCT06419387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Therapy Mobile App
Description: Self-Therapy Mobile App includes videos and guidelines for applying EMDR Flash Technique
Study NCT06419387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education Videos
Description: Psycho-education Videos include guidelines for increasing emotion regulation skills.
Study NCT05446402 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Geologie Acne Regimen - one side of face
Description: Geologie is an over-the-counter cosmetic acne regimen with three products. The regimen also has three levels over the course of three months, in which the nighttime lotion is switched to a stronger formula each month. The Geologie Clear System regimen for acne prone skin includes:~1. Clarifying Gel Cleanser - SA Formula (2% Salicylic Acid)~2. Brightening Day Cream - SPF 15 (5% Azelaic Acid, 2% Hyaluronic Acid, 1%Niacinamide)~3. Repairing Night Cream -~   1. Level 1 (0.05% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  2. Level 2 (0.2% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  3. Level 3 (0.3% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)
Study NCT05446402 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Proactive Acne Regimen - other side of face
Description: ProActiv is an over-the-counter cosmetic regimen with three products. The~Proactiv Solution 3-Piece System regimen includes:~1. Renewing Cleanser (Active ingredient: 2.5% Benzoyl Peroxide)~2. Revitalizing Toner (Glycolic Acid)~3. Repairing Treatment (Active ingredient: 2.5% Benzoyl Peroxide)
Study NCT06233994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).
Study NCT06233994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib Tosilate Tablets
Description: Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).
Study NCT06233994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion, once every 3 weeks (Q3W).
Study NCT06237803 — intervention group
Intervention type: OTHER
Intervention: storage of biological samples
Description: collect and store biological samples
Study NCT06036953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical muscle stimulation
Description: The electric muscle stimulator (EMS) used in this study was from Funcare (Funcare Co., Ltd, Taichung, Taiwan). EMS electrodes were attached to the biceps of both hands, the abdomen, and the quadriceps of both legs sequentially. Each part was stimulated once a day for 30 minutes.
Study NCT04199819 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: entecavir
Description: Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis.
Study NCT04807803 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of Minimal hepatic encephalopathy (MHE)
Description: Assessment of MHE at the inclusion and 6 months after treatment if diagnosed with MHE: Serum ammonia analysis, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT) and evaluation of abdominal imaging, liver and splenic transient elastography, gastroscopy
Study NCT06172920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride
Description: Patients are receiving tramadol hydrochloride under thoracic surgery
Study NCT06172920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldolan
Description: Patients are receiving meperidine under thoracic surgery
Study NCT06172920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine hydrochloride
Description: Patients are receiving Morphine hydrochloride under thoracic surgery
Study NCT04905355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: The VR used during the ambulatory orthopedic surgery allows immersive experience in HD-2D virtual environment. Patient can choose among movies, cartoons, entertainments offered for visualization during the surgery
Study NCT06384664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atricure's crysoSPHERE probe
Description: Cryoablation is a procedure that is used to freeze and burn away tissue cells via a device called a cryosphere which emits a freezing gas.
Study NCT06384664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: An intercostal nerve block involves injecting anesthetic medications into nerves around the thoracic incision to provide temporary longer term pain relief after surgery.